share_log

Exicure | 8-K: Current report

Exicure | 8-K: Current report

Exicure | 8-K:重大事件
美股SEC公告 ·  08/19 11:27

Moomoo AI 已提取核心信息

Exicure, Inc., a biotechnology company, announced the adjournment of its Special Meeting of Stockholders, initially scheduled for August 15, 2024, and reconvened on August 19, 2024. The meeting was adjourned due to the lack of a quorum as proxies submitted represented approximately 49.7% of the outstanding shares, falling short of the majority required. The Special Meeting is rescheduled to reconvene on August 20, 2024, at 9:00 a.m. Central Time, to be held virtually. The company is soliciting additional votes regarding the proposal outlined in the definitive proxy statement filed with the SEC on July 30, 2024. Stockholders who have not voted are urged to do so as soon as possible. Exicure is currently exploring strategic alternatives to maximize stockholder value following its restructuring and suspension of clinical and development activities.
Exicure, Inc., a biotechnology company, announced the adjournment of its Special Meeting of Stockholders, initially scheduled for August 15, 2024, and reconvened on August 19, 2024. The meeting was adjourned due to the lack of a quorum as proxies submitted represented approximately 49.7% of the outstanding shares, falling short of the majority required. The Special Meeting is rescheduled to reconvene on August 20, 2024, at 9:00 a.m. Central Time, to be held virtually. The company is soliciting additional votes regarding the proposal outlined in the definitive proxy statement filed with the SEC on July 30, 2024. Stockholders who have not voted are urged to do so as soon as possible. Exicure is currently exploring strategic alternatives to maximize stockholder value following its restructuring and suspension of clinical and development activities.
生物技术公司Exicure, Inc.宣布其股东特别会议的延期,原定于2024年8月15日举行,并于2024年8月19日重新召开。会议由于缺乏法定人数而被延期,提交的代理投票占公司总股本的约49.7%,未达到所需的多数。特别会议已经重新安排于2024年8月20日于中部时间上午9:00以线上方式进行。该公司正在寻求战略性方案,以最大程度地增加股东价值,因为其已经进行了重组并暂停了临床和开发活动。公司正在征集有关代理声明的提案的额外投票,该提案已于2024年7月30日向美国证券交易委员会提交。敦促尚未表决的股东尽快表决。
生物技术公司Exicure, Inc.宣布其股东特别会议的延期,原定于2024年8月15日举行,并于2024年8月19日重新召开。会议由于缺乏法定人数而被延期,提交的代理投票占公司总股本的约49.7%,未达到所需的多数。特别会议已经重新安排于2024年8月20日于中部时间上午9:00以线上方式进行。该公司正在寻求战略性方案,以最大程度地增加股东价值,因为其已经进行了重组并暂停了临床和开发活动。公司正在征集有关代理声明的提案的额外投票,该提案已于2024年7月30日向美国证券交易委员会提交。敦促尚未表决的股东尽快表决。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息